Stocks soar as Aditxt acquires Evofem in a major deal

  • Shares of Aditxt and Evofem Biosciences surge after $100 million acquisition deal
  • Aditxt’s stock up 85% in premarket trading
  • Evofem’s stock up 71% in premarket trading
  • Aditxt to acquire Evofem in a deal involving $100 million
  • Evofem to establish a women’s health mission within Aditxt’s platform
  • Aditxt aims to accelerate Evofem into the global non-hormonal birth control market
  • Deal approved unanimously by the boards of both companies

Shares of Aditxt and Evofem Biosciences soared after the companies signed a $100 million acquisition deal. Aditxt’s stock was up 85% at $7.03 in premarket trading, after having closed the market on Monday down 92% year-to-date. Evofem’s stock was up 71% at 12 cents in premarket trading, having lost 99% year-to-date at Monday’s market close. The companies said Tuesday morning that Aditxt will acquire Evofem in a deal involving about $100 million in a combination of common stock and preferred stock, as well as the assumption of certain senior debt. Evofem is a commercial-stage women’s health company, and will establish a women’s health mission within Aditxt’s platform, the companies said. Aditxt said it will look to accelerate Evofem into the global non-hormonal birth control market. The boards of both companies have unanimously approved the deal.

Public Companies: Aditxt (Unknown), Evofem Biosciences (Unknown)
Private Companies:
Key People:

Factuality Level: 8
Justification: The article provides factual information about the acquisition deal between Aditxt and Evofem Biosciences. It includes details about the stock prices, the terms of the deal, and the plans for the companies moving forward. There is no obvious bias or opinion presented in the article, and the information is presented in a straightforward manner.

Noise Level: 3
Justification: The article provides relevant information about the acquisition deal between Aditxt and Evofem Biosciences. It includes details about the stock prices and the terms of the deal. However, it lacks in-depth analysis, scientific rigor, and evidence to support the claims made. It also does not provide any actionable insights or explore the consequences of the deal on stakeholders.

Financial Relevance: Yes
Financial Markets Impacted: Aditxt and Evofem Biosciences

Presence of Extreme Event: No
Nature of Extreme Event: No
Impact Rating of the Extreme Event: No
Justification: The article pertains to financial topics as it discusses the acquisition deal between Aditxt and Evofem Biosciences. The deal involves a significant amount of money and will impact the financial markets of both companies. However, there is no mention of any extreme event in the article.

Reported publicly: www.marketwatch.com